Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease (Q38056852)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 2012

Language	Label	Description	Also known as
English	Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease	scientific article published on December 2012

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease (English)

1 reference

Europe PubMed Central

27 August 2017

0 references

1 reference

ChEBI release 2020-05-28

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Susan Duty

1

1 reference

Europe PubMed Central

27 August 2017

publication date

1 December 2012

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

26

1 reference

Europe PubMed Central

27 August 2017

1017-1032

1 reference

Europe PubMed Central

27 August 2017

12

1 reference

Europe PubMed Central

27 August 2017

https://scigraph.springernature.com/pub.10.1007/s40263-012-0016-z

0 references

Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Parkinson's disease. First of two parts

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Functional changes of the basal ganglia circuitry in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Improving symptom control in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The clinical spectrum of levodopa-induced motor complications

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Glutamate and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Metabolic effects of nigrostriatal denervation in basal ganglia.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Molecular mechanisms of L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Metabotropic glutamate receptor II in the brains of Parkinsonian patients

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Phosphorylation of AMPA receptors: mechanisms and synaptic plasticity

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The pathogenesis of cell death in Parkinson's disease--2007.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Glutamate receptors, neurotoxicity and neurodegeneration

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Convergent synaptic input from the neostriatum and the subthalamus onto identified nigrothalamic neurons in the rat.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The cortico-nigral projection: reduced glutamate content in the substantia nigra following frontal cortex ablation in the rat

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Pruning and loss of excitatory synapses by the parkin ubiquitin ligase

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Association between early-onset Parkinson's disease and mutations in the parkin gene

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Causes of Parkinson's disease: genetics of DJ-1

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Alternative excitotoxic hypotheses

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Parkinson's disease and pesticides: a toxicological perspective

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Rotenone reduces Mg2+-dependent block of NMDA currents in substantia nigra dopamine neurons.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Apoptosis in Parkinson's disease: signals for neuronal degradation

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Synaptic localization of ionotropic glutamate receptors in the rat substantia nigra

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Management of punding in Parkinson's disease: an open-label prospective study.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Association between amantadine and the onset of dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in an experimental model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Pharmacologic modulation of MPTP toxicity: MK 801 in prevention of dopaminergic cell death in monkeys and mice

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Characterisation of the expression of NMDA receptors in human astrocytes

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected].

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Metabotropic glutamate receptors in the basal ganglia motor circuit

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mG

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate recept

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0016-Z

21 January 2018

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review of NMDA antagonist-induced neurotoxicity and implications for clinical development.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NMDA antagonists partially protect against MPTP induced neurotoxicity in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular, subcellular, and subsynaptic distribution of AMPA-type glutamate receptor subunits in the neostriatum of the rat.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Free amino acids in the brain of patients with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Success and problems of long-term levodopa therapy in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Small interfering RNA specific for N-methyl-D-aspartate receptor 2B offers neuroprotection to dopamine neurons through activation of MAP kinase.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

GluR1 phosphorylation and persistent expression of levodopa-induced motor response alterations in the Hemi-Parkinsonian rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NMDA receptor blockade reverses motor response alterations induced by levodopa

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etiology and pathogenesis of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

(+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA les

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23114872

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40263-012-0016-Z

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38056852&oldid=2098988493"